Global Acute Ischemic Stroke Therapeutics Market to Reach $14.38 Billion by 2029, Growing at 9.2% CAGR

What Is the Expected Size and Growth Rate of the Acute Ischemic Stroke Therapeutics Market?_x000D_
In recent years, the market size for acute ischemic stroke therapeutics has witnessed significant growth. It is predicted to increase from $9.24 $ billion in 2024 to $10.12 $ billion in 2025, reflecting a compound annual growth rate (CAGR) of 9.5%. The growth observed in the historic period is due to factors such as an uptick in the patient count, an aging population, an escalating prevalence of obesity, an upsurge in ischemic stroke occurrences, and increasing hypertension cases._x000D_
_x000D_
Expectations are high for robust expansion in the acute ischemic stroke therapeutics market in the coming years, with projections placing its value at $14.38 billion by 2029, representing a compound annual growth rate (CAGR) of 9.2%. Factors contributing to this predicted growth span the rising trend towards online pharmacies, an increase in cardiovascular ailments and cholesterol levels, and a mounting prevalence of diseases, including ischemic stroke. The forecast period also signals significant developments in medical technology such as the introduction of artificial intelligence and machine learning, advancements in the field of neurology, and the uptake of high-tech diagnostic tools._x000D_
_x000D_
What Factors Are Fueling Growth in the Acute Ischemic Stroke Therapeutics Market?_x000D_
The upward trend in hypertension cases is anticipated to fuel the expansion of the acute ischemic stroke therapeutics market in the future. Hypertension is a health condition characterized by consistently high blood pressure exerted on the walls of the arteries, leading to an elevated risk of cardiac disease, stroke, and other health issues. The increasing occurrence of this condition is chiefly attributed to the aging population and escalating obesity rates. Therapies for acute ischemic stroke serve to handle the growing issue of hypertension by addressing complications caused by strokes and preventing further damage to the blood vessels in the brain, which is commonly associated with elevated blood pressures. For example, statistics from the National Health Service England, a government department based in the UK, in May 2023 revealed that approximately 30% of the adult US population was living with hypertension, of which 15% had untreated hypertension. Moreover, the rate of hypertension rose with age, varying from 9% in adults between 16 to 44 years old to 60% in those 65 years and older. Thus, the increasing incidence of hypertension promotes the development of the acute ischemic stroke therapeutics market._x000D_
_x000D_
Get Your Free Sample Now - Explore Exclusive Market Insights:_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=19265&type=smp_x000D_
_x000D_
Which Leading Companies Are Shaping the Growth of the Acute Ischemic Stroke Therapeutics Market?_x000D_
Major companies operating in the acute ischemic stroke therapeutics market are Johnson & Johnson, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Medtronic plc, Eli Lilly and Company, Amgen Inc., Stryker Corporation, Teva Pharmaceutical Industries Limited, Merck & Co. Inc., Otsuka Pharmaceutical Co. Ltd., Biogen Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Genentech Inc., NoNO Inc., Athersys Inc., XBiotech Inc., ZZ Biotech LLC_x000D_
_x000D_
What Are the Major Trends Shaping the Acute Ischemic Stroke Therapeutics Market?_x000D_
Leading businesses in the acute ischemic stroke therapeutics market are concentrating on the progression of medical technologies with innovative solutions such as exosome-based therapy for neurological indications. This approach enhances treatment efficiency and betters patient outcomes. Exosome-based therapy for acute ischemic stroke is a groundbreaking strategy that uses exosomes, tiny extracellular vesicles that play a crucial role in intercellular communication. Aruna Bio, an American neural exosome platform developer, achieved a significant breakthrough in January 2024 by gaining the FDA's approval for their investigational new drug application for AB126. This marked the entry of the first exosome-based therapy for human clinical trials aimed at a neurological indication, particularly acute ischemic stroke. A Phase 1b/2a clinical trial is scheduled to commence early in 2024, with a focus on the safety, tolerability, and preliminary efficacy of AB126 on patients who have undergone thrombectomy but have a poor prognosis. AB126, derived from proprietary neural stem cells, has the ability to penetrate the blood-brain barrier and has exhibited anti-inflammatory and neuroprotective effects in preclinical trials._x000D_
_x000D_
What Are the Key Segments of the Acute Ischemic Stroke Therapeutics Market?_x000D_
The acute ischemic stroke therapeuticsmarket covered in this report is segmented -_x000D_
_x000D_
1) By Type: Thrombolytic Therapeutics, Antihypertensive Therapeutics, Antiplatelet Therapeutics, Anticoagulants_x000D_
2) By Route Of Administration: Oral, Parenteral_x000D_
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies_x000D_
4) By Application: Hospitals, Ambulatory Surgical Center, Diagnostic Centers_x000D_
_x000D_
Subsegments:_x000D_
1) By Thrombolytic Therapeutics: Tissue Plasminogen Activators (tPA), Urokinase_x000D_
2) By Antihypertensive Therapeutics: Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Beta Blockers, Calcium Channel Blockers, Diuretics_x000D_
3) By Antiplatelet Therapeutics: Aspirin, Clopidogrel, Ticagrelor, Dipyridamole, Cilostazol_x000D_
4) By Anticoagulants: Vitamin K Antagonists, Direct Oral Anticoagulants (DOACs), Heparins_x000D_
_x000D_
Pre-Book Your Report Now For A Swift Delivery:_x000D_
https://www.thebusinessresearchcompany.com/report/acute-ischemic-stroke-therapeutics-global-market-report_x000D_
_x000D_
Which Region Dominates the Acute Ischemic Stroke Therapeutics Market?_x000D_
North America was the largest region in the acute ischemic stroke therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute ischemic stroke therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
What Is Covered In The Acute Ischemic Stroke Therapeutics Global Market Report?_x000D_
_x000D_
- Market Size Analysis: Analyze the Acute Ischemic Stroke Therapeutics Market size by key regions, countries, product types, and applications._x000D_
- Market Segmentation Analysis: Identify various subsegments within the Acute Ischemic Stroke Therapeutics Market for effective categorization._x000D_
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape._x000D_
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market._x000D_
- Market Contribution: Evaluate contributions of different segments to the overall Acute Ischemic Stroke Therapeutics Market growth._x000D_
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers._x000D_
- Industry Challenges: Analyze challenges and risks affecting the Acute Ischemic Stroke Therapeutics Market._x000D_
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market._x000D_
_x000D_
Unlock Exclusive Market Insights - Purchase Your Research Report Now!_x000D_
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19265

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.